Navigation Links
Eurand Announces Positive Phase III Clinical Study Results

lation, which can be sprinkled on food for easier administration to young children.

The full results of the two phase III trials will be published in peer reviewed journals and presented at upcoming medical meetings in the United States and Europe.

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2000 and has a pipeline of product candidates in development for itself and its partners. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast- dissolving formulations and drug conjugation.

Eurand is a global company with research, development and manufacturing facilities in Milan, Italy, Dayton, Ohio, USA, Trieste, Italy and Paris, France. For more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements.

    (1) Guidance for Industry Exocrine Pancreatic Insufficiency Drug Products

        -Submitting NDAs

        U.S. Department of Health and Human Services, Food and Drug

        Administration (FDA), Center for Drug Evaluation and Research (CDER),

        April 2006

    (2) Federal Register/ Vol. 69 No. 82. April 28, 2004

    (3) Littlewood, 
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand to Present Zentase Phase III Data
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Eurand Announces Positive Phase III Clinical Study Results
(Date:7/21/2014)... 21, 2014 ... "Global biosimilars/follow-on-biologics market (types, applications and geography) - ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... would reach $35 billion by 2020 from the ... clearer regulatory pathways in developed markets and higher ...
(Date:7/21/2014)... 2014 The Louisiana ... CompuMed, Inc. (OTCPink: CMPD) Enterprise Organ Procurement ... recovery. CompuMed Enterprise OPO includes a cloud-based ... its Board-Certified specialists for diagnostic exam interpretations ... (Logo: http://photos.prnewswire.com/prnh/20140721/697628) With CompuMed Enterprise ...
(Date:7/21/2014)... , July 21, 2014  PowerVision, Inc., ... fluid-based accommodating intraocular lens, today announced that ... and Law Chair of Ophthalmology, and Professor of ... the company,s Scientific Advisory Board. ... the American Academy of Ophthalmology Lifetime Achievement award, ...
Breaking Medicine Technology:Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4Louisiana Organ Procurement Agency Leveraging CompuMed to Secure More Donor Hearts 2Louisiana Organ Procurement Agency Leveraging CompuMed to Secure More Donor Hearts 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4
(Date:7/22/2014)... 22, 2014 Recently, 2014quinceaneradresses.com, a popular ... its latest assortment of blue and white Quinceanera ... on these special Quinceanera gowns, hoping to show appreciation ... 30 can get a discounted price, up to 60% ... to announce these new items. As one of the ...
(Date:7/22/2014)... South Carolina (PRWEB) July 22, 2014 One ... loss solution managed to lose 20 pounds. Unfortunately, the weight ... and nauseated for the duration of her time using the ... One woman experienced heart flutters and insomnia as a result ... experienced a heart attack at the age of 37 because ...
(Date:7/22/2014)... IL (PRWEB) July 22, 2014 Hope ... of Matthew Baffoe to their Chicago staff. This addition ... Taff Construction Incorporated (TCI). Hope For The Warriors® is ... members, their families, and families of the fallen who ... of duty. , Baffoe’s work will support programs ...
(Date:7/22/2014)... Garland’s new Energizer BK specially ... as a flood coat over new and existing asphalt ... restoration material. It provides natural resistance to moisture, chemicals, ... life-cycle costs. Energizer BK is specially formulated with an ... in addition to superior strength and flexibility. , ...
(Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
Breaking Medicine News(10 mins):Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2
... pro-health messages can predict if you,ll keep that resolution ... That,s according to a new study forthcoming in ... who were already taking action to quit," says Emily ... of the Communication Neuroscience Laboratory at the U-M Institute ...
... to develop computer-assisted diagnosis tools that will provide ... consistently accurate diagnoses. "The advent of digital ... revolution in imaging technology for histopathology," according to ... Biomedical Informatics at The Ohio State University Medical ...
... the counter has not reduced the number of teenage ... sexually-transmitted diseases (STIs), according to a report by experts ... and Sourafel Girma used local health authority data to ... to offer emergency birth control at pharmacies and without ...
... Having sex while you,re pregnant is generally safe, a new ... review authors. "There are very few proven contraindications and risks ... be reassured." The primer, based on a review of ... Medical Association Journal . Some potential, but uncommon, risks ...
... to build an extra natural layer of nanoparticle-like armour has ... startlingly simple way to give drug bearing polymer vesicles (microscopic ... The Warwick researchers have been able to decorate these ... strategy in the design of vehicles for drug release, for ...
... Scientists have discovered why orchids are one of the most ... to their relationships with the bees that pollinate them and ... the American Naturalist , is the culmination of a ... College London, the Royal Botanic Gardens, Kew, and other international ...
Cached Medicine News:Health News:Resolved to quit smoking? 2Health News:Computer-assisted diagnosis tools to aid pathologists 2Health News:Computer-assisted diagnosis tools to aid pathologists 3Health News:Morning after pill linked to increase in STIs, study shows 2Health News:Morning after pill linked to increase in STIs, study shows 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: